Product Description
BPX-601, the companyÕs first GoCAR-T¨Êproduct candidate, incorporates iMC, BellicumÕs inducible co-activation domain.ÊBPX-601 is being evaluated as a treatment for pancreatic and prostate tumors expressing prostate stem cell antigen (PSCA). (Sourced from: https://ir.bellicum.com/news-releases/news-release-details/bellicum-reports-fda-lifted-clinical-hold-bpx-601-phase-12)
Mechanisms of Action: CAR-T, PSCA
Novel Mechanism: Yes
Modality: CAR-T (Unknown Type)
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bellicum
Company Location: HOUSTON TX 77098
Company CEO: Richard A. Fair
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02744287 |
BP-012 | P2 |
Suspended |
Prostate Cancer |
2025-10-01 |
19% |
2023-04-22 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/14/2023 |
News Article |
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives |
|
02/16/2023 |
News Article |
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium |
|
01/19/2023 |
News Article |
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium |
|
12/11/2022 |
News Article |
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid |